CD274 and neoplasm: CD274 (PD-L1), which is abundantly expressed in many tumours, induces apoptosis in CTL and helps tumour cells to evade immune surveillance by activating CD274 receptors on CTL (cytotoxic T lymphocytes), thereby increasing drug resistance in tumour cells and making them more difficult to treat [33].